Guggenheim reiterates Buy on MBX Biosciences with $150 price target
Guggenheim maintained a Buy rating on MBX Biosciences's stock and set a price target of $150.00, implying a potential upside of 165.3% from the previous closing price.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.